Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages

Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell–intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive patient populations and to design efficient combinato...

Descripción completa

Detalles Bibliográficos
Autores principales: Murgaski, Aleksandar, Kiss, Máté, Van Damme, Helena, Kancheva, Daliya, Vanmeerbeek, Isaure, Keirsse, Jiri, Hadadi, Eva, Brughmans, Jan, Arnouk, Sana M., Hamouda, Ahmed E.I., Debraekeleer, Ayla, Bosteels, Victor, Elkrim, Yvon, Boon, Louis, Hoves, Sabine, Vandamme, Niels, Deschoemaeker, Sofie, Janssens, Sophie, Garg, Abhishek D., Vande Velde, Greetje, Schmittnaegel, Martina, Ries, Carola H., Laoui, Damya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Tumor Biology and Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574379/
https://www.ncbi.nlm.nih.gov/pubmed/35979635
http://dx.doi.org/10.1158/0008-5472.CAN-22-0094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574379/
https://www.ncbi.nlm.nih.gov/pubmed/35979635
http://dx.doi.org/10.1158/0008-5472.CAN-22-0094

Ejemplares similares